Jeffrey M. Witkin

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

Eleni T. Tzavara, Richard J. Davis, Kenneth W. Perry et al. · British Journal of Pharmacology · 2003 · 269 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Allosteric modulation of the muscarinic M ₄ receptor as an approach to treating schizophrenia

Wai‐Yee Chan, David L. McKinzie, Suchira Bose et al. · Proceedings of the National Academy of Sciences · 2008 · 237 citations · Full text

Medicine, Pharmacology, Psychiatry +17

Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac)

Per Svenningsson, Eleni T. Tzavara, Jeffrey M. Witkin et al. · Proceedings of the National Academy of Sciences · 2002 · 230 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections.

Jeffrey M. Witkin, David E. Nichols, Philip Terry et al. · Journal of Pharmacology and Experimental Therapeutics · 1991 · 178 citations

Medicine, Neuroscience, Pharmacology +17

Metabotropic Glutamate 5 Receptor Antagonism Is Associated with Antidepressant-Like Effects in Mice

Xia Li, Anne B. Need, Melvyn Baez et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 163 citations

Medicine, Neuroscience, Pharmacology +17